Interleukin-5 Antagonist class drugs

2 results

  • cinqair

    (Reslizumab)
    Teva Respiratory, LLC
    CINQAIR® is indicated as an add-on maintenance treatment for adults (18+) with severe asthma exhibiting an eosinophilic phenotype. It is not intended for other eosinophilic conditions or for acute bronchospasm relief or status asthmaticus.

  • nucala

    (mepolizumab)
    GlaxoSmithKline LLC
    NUCALA is indicated for the add-on maintenance treatment of severe asthma (ages 6+), chronic rhinosinusitis with nasal polyps (ages 18+), inadequate chronic obstructive pulmonary disease (COPD), eosinophilic granulomatosis with polyangiitis in adults, and hypereosinophilic syndrome in patients aged 12 and older.